Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CV Sciences (CVSI) EBITDA Margin (2016 - 2025)

CV Sciences' EBITDA Margin history spans 13 years, with the latest figure at 5.93% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 2256.0% to 5.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.44%, a 1250.0% increase, with the full-year FY2025 number at 1.44%, up 1250.0% from a year prior.
  • EBITDA Margin hit 5.93% in Q4 2025 for CV Sciences, up from 8.45% in the prior quarter.
  • Over the last five years, EBITDA Margin for CVSI hit a ceiling of 138.91% in Q1 2023 and a floor of 177.96% in Q4 2021.
  • Historically, EBITDA Margin has averaged 23.04% across 5 years, with a median of 16.06% in 2024.
  • Biggest five-year swings in EBITDA Margin: surged 25517bps in 2022 and later crashed -17186bps in 2023.
  • Tracing CVSI's EBITDA Margin over 5 years: stood at 177.96% in 2021, then skyrocketed by 143bps to 77.2% in 2022, then tumbled by -223bps to 94.66% in 2023, then soared by 82bps to 16.63% in 2024, then surged by 136bps to 5.93% in 2025.
  • Business Quant data shows EBITDA Margin for CVSI at 5.93% in Q4 2025, 8.45% in Q3 2025, and 3.62% in Q2 2025.